BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
A Alu, H Lei, X Han, Y Wei, X Wei - Journal of Hematology & Oncology, 2022 - Springer
Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …
Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances
T Wen, J Wang, Y Shi, H Qian, P Liu - Leukemia, 2021 - nature.com
Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential
efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new …
efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new …
Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial
PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity
than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …
than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …
Molecular map of chronic lymphocytic leukemia and its impact on outcome
Recent advances in cancer characterization have consistently revealed marked
heterogeneity, impeding the completion of integrated molecular and clinical maps for each …
heterogeneity, impeding the completion of integrated molecular and clinical maps for each …
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
We report long-term follow-up from the RESONATE-2 phase 3 study of the once-daily
Bruton's tyrosine kinase inhibitor ibrutinib, which is the only targeted therapy with significant …
Bruton's tyrosine kinase inhibitor ibrutinib, which is the only targeted therapy with significant …
Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized …
WG Wierda, JN Allan, T Siddiqi, TJ Kipps… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal
residual disease (MRD)-guided treatment discontinuation following completion of first-line …
residual disease (MRD)-guided treatment discontinuation following completion of first-line …
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged≤ 70 years
with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort …
with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort …
Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects
HY Estupiñán, A Berglöf, R Zain… - Frontiers in cell and …, 2021 - frontiersin.org
The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …
NCCN guidelines® insights: Chronic Lymphocytic leukemia/small Lymphocytic lymphoma, version 3.2022: Featured updates to the NCCN Guidelines
The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine …
(CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine …
[HTML][HTML] First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized …
Abstract iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus
obinutuzumab (n= 113) versus chlorambucil plus obinutuzumab (n= 116) as first-line …
obinutuzumab (n= 113) versus chlorambucil plus obinutuzumab (n= 116) as first-line …